Page 192 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 7
Figure 3. Survival according to end-of-treatment PET-CT scan result.
Patients who have achieved complete metabolic response (CMR) at the end of treatment (EOT) positron emission tomography (PET)-computer tomography (CT) scan experienced a reduced risk of death compared to patients who have not yet achieved CMR (Hazard ratio [HR] 0.1, 95% Confidence interval [CI]: 0.03– 0.33, P<0.001). Response was simplified to “CMR” versus “no-CMR”.
Table 3. Adverse events.
Hematologic
Neutropenia Febrile neutropenia Thrombocytopenia Anemia
Infectious
Vascular disorders
Pulmonary embolism
Deep venous thrombosis Superficial thrombophlebitis
Nervous system disorders (PNP) Gastrointestinal disorders
Hepatobiliary disorders (ALT, AST increased) General disorder
Any*
Grade 2 Grade 3 Grade 4 n%n%n%
1156 10 12 67 2222 4 5
6756 15 18 12 14
2 3 4 5
4 5 25 29 17 20 5 6 11 13 27 32
9 11
12 14
1 1 2 2 5 6 1 1 33 39 14 16
Adverse events (AE) were graded per patient (maximum grade per cycle) according to National Cancer Institute Common Terminology Criteria for AE. AE events grade 1 were not reported.
*In this row each patient is counted only once with the highest grade AE experienced. PNP: polyneuropathy, ALT: alanine transaminase, AST: aspartate transaminase.
190